Synthetic DNA player Touchlight scores $60M round to more than triple manufacturing capacity as mRNA gets hot
With the twin authorizations of Pfizer/BioNTech’s and Moderna’s mRNA vaccines for Covid-19 late last year, the market for starting materials for that type of shot has seen a big boost. One UK player with a new way to manufacture DNA, a key precursor to producing mRNA, is cashing a sizable check to scale up in a big way.
Touchlight has wrangled $60 million in financing to add 11 production suites to its London site specializing in producing synthetic DNA it says can be produced much faster than normal plasmid DNA, the company said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
